PLYX
Polaryx Therapeutics, Inc. Common StockNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$118.63M
P/E Ratio
—
EPS
$-0.14
Beta
—
52W High
$48.91
52W Low
$2.01
50-Day MA
$4.29
200-Day MA
$5.27
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Polaryx Therapeutics, Inc. Common Stock
Polaryx Therapeutics, Inc., clinical-stage biotechnology company, develops small molecule and gene therapy treatments for lysosomal storage disorders. The company is headquartered in Paramus, New Jersey.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | — |
| Operating Margin | 0.00% |
| Return on Equity | -192.20% |
| Return on Assets | -74.40% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $0.05 |
| Price-to-Book | 47.68 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $49.85M |
| Float | $4.28M |
| % Insiders | 69.34% |
| % Institutions | 4.55% |
Historical Volatility
HV 10-Day
102.65%
HV 20-Day
202.47%
HV 30-Day
176.38%
HV 60-Day
160.77%
HV Rank
—
Volatility is currently contracting
Analyst Ratings
Consensus ($10.00 target)
1
Strong BuyMore HEALTHCARE Stocks
Data last updated: 6/13/2026